Investing.com - Financial Markets Worldwide
Open in App

Ipca Laboratories Ltd. (IPCA)

NSE
Symbol
Exchange
Currency
IPCA·NSE·INR
IPCA·BSE·INR
Currency in INR
1,900.60
+10.40(+0.55%)
Closed·

IPCA Financial Summary

Key Ratios

P/E Ratio41.28
Price/Book5.79
Debt / Equity8.49%
Return on Equity13.22%
Dividend Yield0.32%
EBITDA20.09B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
2026
31/03
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa58,30562,481.177,058.889,412.296,471.5
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa36,225.237,251.848,584.158,597.764,855.1
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa10,590.67,033.59,327.413,551.416,251.3
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa8,840.84,713.25,473.57,376.811,411.2
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa76,235.386,264.3111,012.8117,605.5123,701.9
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa14,658.818,058.223,556.423,862.223,069.3
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa55,417.659,153.277,27083,882.795,240.6
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa1,447.881,903.83-6,829.24215.437,901.25
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa8,560.78,058.19,446.513,213.211,419.7
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-8,550.5-7,250-12,917.9-8,695-2,467.7
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa4,267.85,072.4-5,525.5-2,829.8-7,535.3
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa4,319.25,880.5-8,231.91,688.41,416.7
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 44.98%
Dividend Yield
0.32%
Industry Median 0.71%
Annualized payout
6.00
Paid unevenly
5-Years Growth
+8.45%
Growth Streak
Unlock

Analyst Ratings

15 Buy
1 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,733.50
(-8.79% Downside)

Earnings

Latest Release
May 29, 2026
EPS / Forecast
11.80 / 9.33
Revenue / Forecast
23.89B / 23.68B
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Ipca Laboratories's earnings for the latest quarter?

The Ipca Laboratories EPS (TTM) is 44.98. Ipca Laboratories reported sales of 23,893.00, net income of 2,990.70, and EPS of 11.80 for the latest quarter.

What was Ipca Laboratories's net income for the latest quarter?

Ipca Laboratories's net income for the latest quarter was 2,990.70.

How did Ipca Laboratories's performance compare year-over-year in the latest quarter?

The company's revenue moved from 23,925.00 million INR in the previous quarter to 23,893.00 million INR in the latest quarter, and net income moved from 3,262.70 million INR to 2,990.70 million INR compared to the previous quarter.

What is Ipca Laboratories's net profit margin on a TTM basis?

Ipca Laboratories's trailing twelve months (TTM) net profit margin is 11.83%.

How does Ipca Laboratories's debt to equity ratio compare to industry standards?

Ipca Laboratories's total debt-to-equity ratio is 8.49%.

What is Ipca Laboratories's return on investment on a TTM basis?

Ipca Laboratories's trailing twelve months (TTM) return on investment (ROI) is 13.22%.

How has Ipca Laboratories's total revenue grown this year?

Ipca Laboratories's total revenue was 23,925.00 million INR in the previous quarter and 23,893.00 million INR in the latest quarter.

What is Ipca Laboratories's gross margin on a TTM basis?

Ipca Laboratories's trailing twelve months (TTM) gross margin is 67.23%%.

What was Ipca Laboratories's revenue per share for the latest quarter?

Ipca Laboratories's revenue per share for the latest quarter was 328.77.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.